Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women
Latha Kadalayil, Sofia Khan, Heli Nevanlinna, Peter A Fasching, Fergus J Couch, John L Hopper, Jianjun Liu, Tom Maishman, Lorraine Durcan, Sue Gerty, Carl Blomqvist, Brigitte Rack, Wolfgang Janni, Andrew Collins, Diana Eccles, William Tapper
Nature Communications | NATURE PUBLISHING GROUP | Published : 2017
Awarded by Academy of Finland
Awarded by Specialized Program of Research Excellence (SPORE) in Breast Cancer
W.T., D.E., A.C. and L.K. were supported by Breast Cancer Now. L.K. was also supported by the Faculty of Natural and Environmental Sciences, University of Southampton. The Australian Breast Cancer Family Study (ABCFS) and J.L.H. were supported by the National Health and Medical Research Council (NHMRC), Victorian Health Promotion Foundation, Cancer Council New South Wales, Cancer Council Victoria, Cancer Australia and National Breast Cancer Foundation. The Helsinki Breast Cancer Study (HEBCS) thanks Dr. Kristiina Aittomaki and research nurse Irja Erkkila for their help with collecting patient data and samples. HEBCS has been supported by the Helsinki University Central Hospital Research Fund, the Academy of Finland (266528), the Sigrid Juselius Foundation and the Cancer Society of Finland. Work in Singapore by J.L. was funded by the Agency for Science, Technology and Research (A*STAR). Work in America by F.J.C was funded by The Breast Cancer Research Foundation and a Specialized Program of Research Excellence (SPORE) in Breast Cancer to Mayo Clinic (P50 CA116201).